ЭФФЕКТИВНОСТЬ МОНТЕЛУКАСТА В УСЛОВИЯХ ПЕРСИСТЕНЦИИ АТОПИЧЕСКОЙ БРОНХИАЛЬНОЙ АСТМЫ (original) (raw)

ЭФФЕКТИВНОСТЬ МОНТЕЛУКАСТА В УСЛОВИЯХ ПЕРСИСТЕНЦИИ АТОПИЧЕСКОЙ БРОНХИАЛЬНОЙ АСТМЫ

Aim. To evaluate the montelukast`s effect on level of forced expiratory volume on first second (FEV1) and serum immunoglobulin E (Ig E) in women with persistent atopic asthma. Materials and methods. 95 patients with persistent atopic asthma were observed. They were divided into 2 groups: main group – 60 patients who received montelukast (10 mg, orally), as add-on therapy to inhaled corticosteroids (ICS) and bronchodilators, and compared group 35 patients who received only ICS and bronchodilators. Level of Ig E was assayed with electrochemiluminescence immunoassay analyzer in addition to general examination and spirometry. Results. It was not observed significant difference in Ig E level in both groups. In the main group level of Ig E was 306,5±17,98 IU/ml, while in the compared group – 301,1±26,16 IU/ml. By the end of the study there was a statistically significant decrease of Ig E level only in the main group - 128,6±8,54 IU/ml (p<0,001). The indicators of the FEV1 at main and compared groups after treatment significantly increased (p<0,05), also there was statistically difference (p<0,05) between main (FEV1 – 82,2±0,18 %) and compared (FEV1 – 87,3±0,32 %) groups. The data indicated a correlation between level of serum Ig E and FEV1. Conclusions. Montelukast improves clinical, functional manifestations of persistent atopic asthma in women and increases anti-inflammatory effects.